As part of the urgent global race to tackle the coronavirus outbreak, Novavax (NVAX) is due to commence Phase 1 testing for its SARS-CoV-2 vaccine, NVX-CoV2373, within the coming weeks.According to the statement, this is the third confirmed global Covid-19 vaccine trial and the first in Australia.“The urgent global race to develop a vaccine against the COVID-19 pandemic drove our rapid identification and selection of an optimal, highly immunogenic vaccine candidate,” said Stanley C. Erck, President and CEO of Novavax.The Phase 1 in-human trial of NVX-CoV2373 is expected to begin in mid-May with preliminary immunogenicity and safety results in July, …read more
Source:: Yahoo Finance
